- Home
- RADX vs AKTX Comparison
RADX vs AKTX Comparison
Compare RADX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- AKTX
- Stock Information
- Founded
- RADX 2021
- AKTX N/A
- Country
- RADX Australia
- AKTX United States
- Employees
- RADX N/A
- AKTX N/A
- Industry
- RADX
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- AKTX Health Care
- Exchange
- RADX NYSE
- AKTX Nasdaq
- Market Cap
- RADX 32.5M
- AKTX 35.7M
- IPO Year
- RADX N/A
- AKTX N/A
- Fundamental
- Price
- RADX $5.35
- AKTX $1.01
- Analyst Decision
- RADX Strong Buy
- AKTX Strong Buy
- Analyst Count
- RADX 3
- AKTX 1
- Target Price
- RADX $15.00
- AKTX $5.00
- AVG Volume (30 Days)
- RADX 17.5K
- AKTX 25.1K
- Earning Date
- RADX 02-26-2025
- AKTX 08-18-2025
- Dividend Yield
- RADX N/A
- AKTX N/A
- EPS Growth
- RADX N/A
- AKTX N/A
- EPS
- RADX N/A
- AKTX N/A
- Revenue
- RADX $204,609.00
- AKTX N/A
- Revenue This Year
- RADX N/A
- AKTX N/A
- Revenue Next Year
- RADX N/A
- AKTX N/A
- P/E Ratio
- RADX N/A
- AKTX N/A
- Revenue Growth
- RADX N/A
- AKTX N/A
- 52 Week Low
- RADX $3.50
- AKTX $0.85
- 52 Week High
- RADX $50.82
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- AKTX 33.43
- Support Level
- RADX N/A
- AKTX $1.01
- Resistance Level
- RADX N/A
- AKTX $1.15
- Average True Range (ATR)
- RADX 0.00
- AKTX 0.04
- MACD
- RADX 0.00
- AKTX -0.01
- Stochastic Oscillator
- RADX 0.00
- AKTX 6.60
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.